3 results
Approved WMORecruiting
To determine the effect of lithium treatment (plasma levels between 0,4-0,8 mEq/liter) versus placebo - in addition to riluzole 2dd 50 mg - on reaching a clinical endpoint in patients with ALS.
Approved WMORecruiting
To determine the objective response rate of entrectinib, as assessed by BICR, in each patient population basket of solid tumors that harbor anNTRK1/2/3, ROS1, or ALK gene rearrangement
Approved WMORecruiting
To investigate the efficacy and safety of drugs for patients with ALS.